COMBINING TO CURE®
Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.
Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
May 27, 2020
Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC
October 29, 2020
NSCLC
mCRPC
CRC
PDAC
Advanced Malignancies
Domvanalimab
(DOM)
Anti-TIGIT Antibody
NSCLC
NSCLC
Multiple Cancer Types
Etrumadenant
(ETRUMA)
Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule
CRPC
CRC
NSCLC
NSCLC
Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb
These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.
ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Quemli: quemliclustat; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care
CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma;
PARTNERSHIPS & COLLABORATIONS:
(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.
(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).
||Clinical collaboration with Infinity Pharmaceuticals.
*+/- biologic
Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb
These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.
ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Quemli: quemliclustat; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care
CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma;
PARTNERSHIPS & COLLABORATIONS:
(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.
(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).
||Clinical collaboration with Infinity Pharmaceuticals.
*+/- biologic
HIF-2𝛂 Inhibitor
Transcription factor
Cancer cell intrinsic target; potential non-oncology indications
HIF-2α is a master transcriptional regulator of multiple genes involved in tumor progression.1
AXL Inhibitor
Tyrosine kinase
Cancer cell intrinsic target
AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.2
PI3Kγ Inhibitor
Glycolipid kinase
Immune (TAM, MDSC) target
PI3Kγ is required for the immunosuppressive activity of tumor-infiltrating macrophages and myeloid-derived suppressor cells.3
PAK4 Inhibitor
Serine kinase
Cancer cell intrinsic target
PAK4 overexpression is responsible for T cell exclusion from immune desert tumors.4
Anti-TIM-3 Antibody
Immune Checkpoint
Cancer cell intrinsic and immune (T cell) target
TIM-3 is an immune checkpoint highly overexpressed by leukemic cells (eg, MDS, AML) and exhausted T cells.5
AML, acute myeloid leukemia; HIF-2𝛂, hypoxia-inducible factor 2-alpha; MDS, myelodysplastic syndromes; PAK-4, p21-activated kinase 4; PI3Kγ, phosphatidylinositol 3-kinase-gamma; TIM-3, T cell immunoglobulin and mucin-domain containing-3.
References: 1. Murugesan T, Rajajeyabalachandran G, Kumar S, Nagaraju S, Kumar S. Targeting HIF-2α as therapy for advanced cancers. Drug Discov Today. 2018;23(7):1444-1451. 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369. 3. Foubert P, Kaneda MM, Varner JA. PI3Kγ activates integrin α4 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol Res. 2017;5(11):957-968. 4. Abril-Rodriguez G, Torrejon DY, Liu W, et al. PAK4 inhibition improves PD-1 blockade immunotherapy. Nature Cancer. 2020;1:46-58. 5. Toshio A, Tamura H, Ishibashi M, et al. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget. 2017;8(51):88904-88917.
